News & Updates

WASHINGTON, D.C. — Patients For Affordable Drugs Executive Director, Ben Wakana, issued the following statement regarding the announcement that Aetna plans to pass drug rebates to consumers:

“The recent changes announced by Aetna and United will offer some relief to about 10.5 million people — 3 percent of the U.S. population. These announcements are designed to protect secret and often anti-competitive practices of PBMs and insurers. Rebates fail to lower list drug prices which millions of Americans are forced to pay.

A new Kaiser Family Foundation Health Tracking Poll found an overwhelming 72 percent of people think the drug industry has too much influence in Washington, outpolling Wall Street and the gun lobby.

I'm Pam Holt, and I have cancer. I had to take on $10,000 in debt to pay for Revlimid. But, I told myself, the company needed this money for research. I was wrong. This is what I just did about it:

Novartis' taxpayer-funded drug Kymriah is overpriced by $315,000 per treatment